Literature DB >> 24470204

Is there a role for the incretin system in blood pressure regulation?

Akhilesh Rao1, Ravi Nistala.   

Abstract

Incretin-based therapies are now well established for diabetes management and are among the frontline agents for control of hyperglycemia. In addition to their antihyperglycemic effects, evidence is emerging on the role of these agents on blood pressure regulation, cardioprotective and renoprotective properties. Because of the pleiotropic nature of these affects, these agents could offer significant benefits with regards to the cardiorenal metabolic complications that are part of the diabetes and obesity epidemic in the United States and worldwide. We review the various known mechanisms or pathways by which incretin based therapy exerts its regulation of blood pressure with emphasis on novel mechanisms such as inflammation/immunomodulation and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24470204     DOI: 10.1007/s11906-013-0417-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  57 in total

1.  High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway.

Authors:  Hyun Wha Chung; Ji Hee Lim; Min Young Kim; Seok Joon Shin; Sungjin Chung; Bum Soon Choi; Hyung Wook Kim; Yong-Soo Kim; Cheol Whee Park; Yoon Sik Chang
Journal:  Nephrol Dial Transplant       Date:  2011-11-09       Impact factor: 5.992

2.  Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.

Authors:  Annis Marney; Siri Kunchakarra; Loretta Byrne; Nancy J Brown
Journal:  Hypertension       Date:  2010-08-02       Impact factor: 10.190

Review 3.  Potential benefits of rho-kinase inhibition in arterial hypertension.

Authors:  Olaf Grisk
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

4.  Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

Authors:  Grace Flock; Laurie L Baggio; Christine Longuet; Daniel J Drucker
Journal:  Diabetes       Date:  2007-08-23       Impact factor: 9.461

Review 5.  The immune system: role in hypertension.

Authors:  Ernesto L Schiffrin
Journal:  Can J Cardiol       Date:  2012-08-15       Impact factor: 5.223

6.  Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.

Authors:  Nasib Ervinna; Tomoya Mita; Eisuke Yasunari; Kosuke Azuma; Rica Tanaka; Satoshi Fujimura; Dewi Sukmawati; Takashi Nomiyama; Akio Kanazawa; Ryuzo Kawamori; Yoshio Fujitani; Hirotaka Watada
Journal:  Endocrinology       Date:  2013-01-21       Impact factor: 4.736

7.  Protective role of the endothelial isoform of nitric oxide synthase in ANG II-induced inflammatory responses in the kidney.

Authors:  Curtis Whiting; Alexander Castillo; Mohammed Z Haque; Dewan S A Majid
Journal:  Am J Physiol Renal Physiol       Date:  2013-08-07

Review 8.  Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.

Authors:  Mohammad Katout; Hong Zhu; Jessica Rutsky; Parthy Shah; Robert D Brook; Jixin Zhong; Sanjay Rajagopalan
Journal:  Am J Hypertens       Date:  2013-11-21       Impact factor: 2.689

9.  Role of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells.

Authors:  Dongmei Cheng; Xiao Zhu; Delbert G Gillespie; Edwin K Jackson
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-09

10.  Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism.

Authors:  Dongjuan Wang; Peng Luo; Yabin Wang; Weijie Li; Chen Wang; Dongdong Sun; Rongqing Zhang; Tao Su; Xiaowei Ma; Chao Zeng; Haichang Wang; Jun Ren; Feng Cao
Journal:  Diabetes       Date:  2013-01-30       Impact factor: 9.461

View more
  1 in total

1.  Risk Factors in Adolescent Hypertension.

Authors:  D Rose Ewald; Lauren A Haldeman PhD
Journal:  Glob Pediatr Health       Date:  2016-02-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.